Mustang Bio Inc Stock News

Wall Street analysts expect Mustang Bio, Inc. (NASDAQ:MBIO) to report earnings of ($0.20) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Mustang Bios earnings. The highest EPS estimate is ($0.18) and the lowest is ($0.21). Mustang Bio posted earnings of ($0.32) per share in the same quarter last year, []

Prudential Financial Inc. purchased a new position in Mustang Bio, Inc. (NASDAQ:MBIO) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 12,799 shares of the companys stock, valued at approximately $42,000. A number of other hedge funds also recently bought and sold []

Renaissance Technologies LLC cut its position in Mustang Bio, Inc. (NASDAQ:MBIO) by 98.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,200 shares of the companys stock after selling 785,200 shares during the quarter. Renaissance Technologies LLCs holdings in Mustang Bio were []

Mustang Bio Inc. (NASDAQ:MBIO) has a beta value of 1.59 and has seen 1.29 million shares traded in the last trading session. The company, currently valued at $190.05M, closed the last trade at $2.08 per share which meant it lost -$0.1 on the day or -4.59% during that session. The MBIO stock price is -150.96% An In-Depth Look At Mustang Bio Inc. (MBIO) Read More »

Mustang Bio, Inc. (NASDAQ:MBIO) Stock analysts at B. Riley boosted their FY2021 EPS estimates for Mustang Bio in a research note issued on Wednesday, November 17th. B. Riley analyst M. Mamtani now anticipates that the company will post earnings per share of ($0.74) for the year, up from their previous forecast of ($0.76). B. []

Mustang Bio Inc. (NASDAQ:MBIO) price on Friday, November 19, rose 2.25% above its previous days close as an upside momentum from buyers pushed the stocks value to $2.27. A look at the stocks price movement, the close in the last trading session was $2.22, moving within a range at $2.20 and $2.28. The beta value Mustang Bio Inc. (NASDAQ: MBIO) Up 2.25%: This Is What Analysts Are Now Forecasting Read More »

Mustang Bio, Inc. (NASDAQ:MBIO) Research analysts at Oppenheimer decreased their FY2021 EPS estimates for shares of Mustang Bio in a research note issued on Tuesday, November 16th. Oppenheimer analyst M. Breidenbach now anticipates that the company will earn ($0.72) per share for the year, down from their previous estimate of ($0.66). Oppenheimer also issued []

Nuveen Asset Management LLC lowered its stake in shares of Mustang Bio, Inc. (NASDAQ:MBIO) by 15.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,799,480 shares of the companys stock after selling 334,703 shares during the quarter. Nuveen Asset Management []

Mustang Bio, Inc. (NASDAQ:MBIO) – Cantor Fitzgerald dropped their FY2021 earnings estimates for shares of Mustang Bio in a report released on Monday, November 15th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings of ($0.73) per share for the year, down from their previous estimate of ($0.68). Cantor Fitzgerald has […]

Mustang Bio Inc. (NASDAQ:MBIO) price closed lower on Friday, November 12, dropping -2.02% below its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

Mustang Bio (NASDAQ:MBIO) posted its earnings results on Thursday. The company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters consensus estimate of ($0.18) by ($0.01), MarketWatch Earnings reports. Shares of Mustang Bio stock traded down $0.05 during trading on Friday, reaching $2.43. The companys stock had a trading volume of 1,021,079 []

Mustang Bio Inc (NASDAQ: MBIO) has been awarded a grant of approximately $2 million from the National Cancer Institute of the National Institutes of Health (NIH).  The two-year award will partiall

WORCESTER, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs i

Christine Brown, Ph.D., of City of Hope will present at the First Annual Conference on CNS Clinical Trials Co-sponsored by SNO and ASCO and the AACR Virtual Special Conference: Brain Cancer Christine

Mustang Bio (MBIO) has been struggling lately, but the selling pressure may be coming to an end soon.